Sign in
Taking people in United StatesPhase 1

Studies blood vessel function in adults with lung, heart or blood pressure disease

Tests vessel-relaxing and vessel-narrowing substances in adults with lung or heart disease.

Key facts

Who runs it
D. Walter Wray
Where
Salt Lake City, United StatesSee the site
Trial code
Registry title
: Vascular Function in Health and Disease
Status
Recruiting
Phase
Phase 1
People taking part
420 people, planned
Started
Sept 2008
Expected to end
Aug 2030
Type of study
Interventional, 7 groups
Treatments tested
  • Maximum Exercise Tests
  • BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate
  • BQ-123
  • Fexofenadine, Ranitidine
  • Angiotensin-II, Valsartan
  • Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine, Phentolamine
  • BQ-123, MitoQ, BH4
Record updated
25 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for healthy young and older volunteers, and for adults with COPD, pulmonary arterial hypertension, heart failure, high blood pressure, or who are having a routine coronary angiography.

Age
18 years or older. Healthy young volunteers are 18-30 years old. Healthy older volunteers are 65 years or older.
Sex
Men and women can join.
Disease stage
COPD: mild to moderate. Pulmonary arterial hypertension: idiopathic or heritable Group 1. Heart failure: New York Heart Association Class I, II or III symptoms. Hypertension: chronic high blood pressure.

Main reasons for not taking part

  • Severe COPD (use of supplemental oxygen, or one-second forced expiratory volume of less than 30% predicted)
  • History of heart attack, coronary artery stenting or bypass surgery
  • Unstable angina or history of variant angina
  • Ejection fraction < 50%
  • Significant kidney disease (Glomerular Filtration Rate < 50 mL/min/1.73m2)

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Healthy Young Volunteers: 18-30 years of age with no diseases or conditions that would affect their participation in the study
  • Healthy Older Controls: volunteers 65 years of age or older with no diseases or conditions that would affect their participation in the study
  • Coronary Angiography subjects: patients undergoing routine coronary angiography
  • Chronic Obstructive Pulmonary Disease subjects: patients diagnosed with mild to moderate COPD
  • Pulmonary Arterial Hypertension subjects: patients with idiopathic or heritable Group 1 pulmonary arterial hypertension
  • Heart Failure subjects: patients with Class I, II or III New York Heart Association symptoms of Heart Failure
  • Hypertension subjects: patients diagnosed with chronic high blood pressure

Who cannot take part

  • History of myocardial infarction
  • History of percutaneous coronary revascularization
  • History of coronary artery bypass grafting
  • Unstable angina pectoris
  • History of variant angina
  • Significant renal disease (Glomerular Filtration Rate < 50 mL/min/1.73m2)
  • Subjects whose medical care or safety may be at risk from undergoing a Magnetic Resonance Imaging examination (e.g. pacemaker, metal implants, certain types of heart valves)
  • Subject has physical ailments (other than COPD, PAH, HF, or hypertension) that would prevent them from study participation in the judgment of the investigator
  • Ejection fraction < 50%
  • Severe COPD (use of supplemental oxygen, or have a one-second forced expiratory volume of less than 30% predicted)
  • Subject is pregnant

This trial is currently available in United States.

  • University of UtahSalt Lake City, United StatesContact: David W Wray, Ph.D.Taking people

About the trial

What the trial wants to find out

Many control mechanisms exist which successfully match the supply of blood with the metabolic demand of various tissues under wide-ranging conditions. One primary regulator of vasomotion and thus perfusion to the muscle tissue is the host of chemical factors originating from the vascular endothelium and the muscle tissue, which collectively sets the level of vascular tone. With advancing age and in many disease states, deleterious adaptations in the production and sensitivity of these vasodilator and vasoconstrictor substances may be observed, leading to a reduction in skeletal muscle blood flow and compromised perfusion to the muscle tissue. Adequate perfusion is particularly important during exercise to meet the increased metabolic demand of the exercising tissue, and thus any condition that reduces tissue perfusion may limit the capacity for physical activity. As it is now well established that regular physical activity is a key component in maintaining cardiovascular health with advancing age, there is a clear need for further studies in populations where vascular dysfunction is compromised, with the goal of identifying the mechanisms responsible for the dysfunction and exploring whether these maladaptations may be remediable. Thus, to better understand the etiology of these vascular adaptations in health and disease, the current proposal is designed to study changes in vascular function with advancing age, and also examine peripheral vascular changes in patients suffering from chronic obstructive pulmonary disease (COPD), Sepsis, Pulmonary Hypertension, and cardiovascular disease. While there are clearly a host of vasoactive substances which collectively act to govern vasoconstriction both at rest and during exercise, four specific pathways that may be implicated have been identified in these populations: Angiotensin-II (ANG-II), Endothelin-1 (ET-1), Nitric Oxide (NO), and oxidative stress.

The 7 groups in the trial

  • Healthy Young Volunteers (18-30 years)Treatment being tested

    Healthy volunteers between the ages of 18 and 30 years with no diseases or conditions that would affect their participation in the study, administered various treatments to assess their effect on blood flow and metabolic demand of tissues under wide-ranging conditions, including Maximum Exercise Tests, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid, L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Norepinephrine, Phentolamine and MitoQ.

    Treatment: Maximum Exercise Tests, BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine, Phentolamine, and BQ-123, MitoQ, BH4

  • Healthy Older Controls (over 65 years)Treatment being tested

    Healthy volunteers 65 years of age or older with no diseases or conditions that would affect their participation in the study, administered various treatments to assess their effect on blood flow and metabolic demand of tissues under wide-ranging conditions, including Maximum Exercise Tests, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid, L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Norepinephrine, Phentolamine and MitoQ.

    Treatment: Maximum Exercise Tests, BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine, Phentolamine, and BQ-123, MitoQ, BH4

  • Coronary Angiography patientsTreatment being tested

    Patients undergoing routine coronary angiography, but who do not require intracoronary procedures or have history of myocardial disease, administered various treatments to assess their effect on blood flow and metabolic demand of tissues under wide-ranging conditions, including Maximum Exercise Tests, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid, L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Norepinephrine, Phentolamine and MitoQ.

    Treatment: Maximum Exercise Tests, BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine, Phentolamine, and BQ-123, MitoQ, BH4

  • Chronic Obstructive Pulmonary Disease patientsTreatment being tested

    Patients diagnosed with mild to moderate COPD, but not severe COPD patients, administered various treatments to assess their effect on blood flow and metabolic demand of tissues under wide-ranging conditions, including Maximum Exercise Tests, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid, L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Norepinephrine, Phentolamine and MitoQ.

    Treatment: Maximum Exercise Tests, BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine, Phentolamine, and BQ-123, MitoQ, BH4

  • Pulmonary Arterial Hypertension patientsTreatment being tested

    Patients with idiopathic or heritable Group 1 pulmonary arterial hypertension, administered various treatments to assess their effect on blood flow and metabolic demand of tissues under wide-ranging conditions, including Maximum Exercise Tests, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid, L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Norepinephrine, Phentolamine and MitoQ.

    Treatment: Maximum Exercise Tests, BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine, Phentolamine, and BQ-123, MitoQ, BH4

  • Heart Failure patientsTreatment being tested

    Patients with Class I - III New York Heart Association symptoms of Heart Failure who are not anemic or taking medications that affect blood clotting, administered various treatments to assess their effect on blood flow and metabolic demand of tissues under wide-ranging conditions, including Maximum Exercise Tests, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid, L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Norepinephrine, Phentolamine and MitoQ.

    Treatment: Maximum Exercise Tests, BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine, Phentolamine, and BQ-123, MitoQ, BH4

  • Hypertension patientsTreatment being tested

    Patients with chronic high blood pressure, but with less than severe hypertension, administered various treatments to assess their effect on blood flow and metabolic demand of tissues under wide-ranging conditions, including Maximum Exercise Tests, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid, L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Norepinephrine, Phentolamine and MitoQ.

    Treatment: Maximum Exercise Tests, BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine, Phentolamine, and BQ-123, MitoQ, BH4

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Vascular Function in Health & Disease: Rehabilitation for Hypertension; Exercise and Skeletal Muscle Afferent Feedback
Plain-language title
Studies blood vessel function in adults with lung, heart or blood pressure diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
25 September 2026